Quadruple wild-type (WT) GIST: Defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways

Maria A. Pantaleo; Margherita Nannini; Christopher L. Corless; Michael C. Heinrich

doi:10.1002/cam4.325

Quadruple wild-type (WT) GIST: Defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways

Maria A. Pantaleo, Margherita Nannini, Christopher L. Corless, Michael C. Heinrich

Knight Cancer Institute

Research output: Contribution to journal › Article › peer-review

76 Scopus citations

Abstract

A subset of GISTs lack mutations in the KIT/PDGFRA or RAS pathways and yet retain an intact succinate dehydrogensase (SDH) complex. We propose that these KIT/PDGFRA/SDH/RAS-P WT GIST tumors be designated as quadruple wild-type (WT) GIST. Further molecular and clinicophatological characterization of quadruple WT GIST will help to determine their prognosis as well as assist in the optimization of medical management, including clinical test of novel therapies.

Original language	English (US)
Pages (from-to)	101-103
Number of pages	3
Journal	Cancer medicine
Volume	4
Issue number	1
DOIs	https://doi.org/10.1002/cam4.325
State	Published - Jan 1 2015

Keywords

BRAF
GIST
Gastrointestinal stromal tumors
NF-1
Quadruple WT
Quadruple negative
RAS
SDH deficiency
SDHA
SDHB
Wild type

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Cancer Research

Access to Document

10.1002/cam4.325

Cite this

@article{16aa2655462f40d1bbbe54988d5ab796,

title = "Quadruple wild-type (WT) GIST: Defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways",

abstract = "A subset of GISTs lack mutations in the KIT/PDGFRA or RAS pathways and yet retain an intact succinate dehydrogensase (SDH) complex. We propose that these KIT/PDGFRA/SDH/RAS-P WT GIST tumors be designated as quadruple wild-type (WT) GIST. Further molecular and clinicophatological characterization of quadruple WT GIST will help to determine their prognosis as well as assist in the optimization of medical management, including clinical test of novel therapies.",

keywords = "BRAF, GIST, Gastrointestinal stromal tumors, NF-1, Quadruple WT, Quadruple negative, RAS, SDH deficiency, SDHA, SDHB, Wild type",

author = "Pantaleo, {Maria A.} and Margherita Nannini and Corless, {Christopher L.} and Heinrich, {Michael C.}",

note = "Publisher Copyright: {\textcopyright} 2014 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.",

year = "2015",

month = jan,

day = "1",

doi = "10.1002/cam4.325",

language = "English (US)",

volume = "4",

pages = "101--103",

journal = "Cancer medicine",

issn = "2045-7634",

publisher = "John Wiley and Sons Ltd",

number = "1",

}

TY - JOUR

T1 - Quadruple wild-type (WT) GIST

T2 - Defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways

AU - Pantaleo, Maria A.

AU - Nannini, Margherita

AU - Corless, Christopher L.

AU - Heinrich, Michael C.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - A subset of GISTs lack mutations in the KIT/PDGFRA or RAS pathways and yet retain an intact succinate dehydrogensase (SDH) complex. We propose that these KIT/PDGFRA/SDH/RAS-P WT GIST tumors be designated as quadruple wild-type (WT) GIST. Further molecular and clinicophatological characterization of quadruple WT GIST will help to determine their prognosis as well as assist in the optimization of medical management, including clinical test of novel therapies.

AB - A subset of GISTs lack mutations in the KIT/PDGFRA or RAS pathways and yet retain an intact succinate dehydrogensase (SDH) complex. We propose that these KIT/PDGFRA/SDH/RAS-P WT GIST tumors be designated as quadruple wild-type (WT) GIST. Further molecular and clinicophatological characterization of quadruple WT GIST will help to determine their prognosis as well as assist in the optimization of medical management, including clinical test of novel therapies.

KW - BRAF

KW - GIST

KW - Gastrointestinal stromal tumors

KW - NF-1

KW - Quadruple WT

KW - Quadruple negative

KW - RAS

KW - SDH deficiency

KW - SDHA

KW - SDHB

KW - Wild type

UR - http://www.scopus.com/inward/record.url?scp=85005769283&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85005769283&partnerID=8YFLogxK

U2 - 10.1002/cam4.325

DO - 10.1002/cam4.325

M3 - Article

C2 - 25165019

AN - SCOPUS:85005769283

SN - 2045-7634

VL - 4

SP - 101

EP - 103

JO - Cancer medicine

JF - Cancer medicine

IS - 1

ER -

Quadruple wild-type (WT) GIST: Defining the subset of GIST that lacks abnormalities of KIT, PDGFRA, SDH, or RAS signaling pathways

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this